Targets › RHD
1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Apr 2029.
May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane. (UniProt, Q02161)
Open in Phaseline: the race on RHD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | RH genotype matched RBC transfusions Transfusion of red blood cells matched at RHD and RHCE loci to reduce alloimmunization | RHD, RHCE | Phase 1 | Sickle Cells Disease | Apr 2029 |
Sickle Cells Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.